CSD/BSE&NSE/2023-24
February 23, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that our Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India, have completed the Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration (US FDA) today. The inspection was conducted from February 12, 2024, to February 23, 2024, and we are pleased to inform you that no Form 483 has been issued as a result of the inspection.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**

HANUMANTHA RAO KOKKONDA
Digitally signed by HANUMANTHA RAO KOKKONDA
Date: 2024.02.23 16:17:29 +05'30'

K. Hanumantha Rao
Company Secretary